Alzheimer Scotland Supports Appeal Judgment On NICE Cost-effectiveness Disclosure
May 15th 2008Drug InformationAlzheimer's / Dementia News XML/RSS Feed
The Court of Appeal ruled in favour of the drug companies Pfizer and Eisai, by finding that the National Institute for Health and Clinical Excellence (NICE) should have allowed public access to the health economics model used to determine the cost-effectiveness of key treatments in people with early stage Alzheimer’s. Three judges found that the process by which NICE decided to restrict the anti-dementia medicines for newly diagnosed patients with mild Alzheimer’s was procedurally unfair.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
